Your browser doesn't support javascript.
loading
BioPrev-C - development and validation of a contemporary prostate cancer risk calculator.
Hermanns, Thomas; Wettstein, Marian S; Kaufmann, Basil; Lautenbach, Noémie; Kaufmann, Ernest; Saba, Karim; Schmid, Florian A; Hötker, Andreas M; Müntener, Michael; Umbehr, Martin; Poyet, Cédric.
Afiliación
  • Hermanns T; Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
  • Wettstein MS; Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
  • Kaufmann B; Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
  • Lautenbach N; Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
  • Kaufmann E; Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
  • Saba K; Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
  • Schmid FA; Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
  • Hötker AM; Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Müntener M; Department of Urology, Stadtspital Triemli, Zürich, Switzerland.
  • Umbehr M; Department of Urology, Stadtspital Triemli, Zürich, Switzerland.
  • Poyet C; Department of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
Front Oncol ; 14: 1343999, 2024.
Article en En | MEDLINE | ID: mdl-38450183
ABSTRACT

Objectives:

To develop a novel biopsy prostate cancer (PCa) prevention calculator (BioPrev-C) using data from a prospective cohort all undergoing mpMRI targeted and transperineal template saturation biopsy. Materials and

methods:

Data of all men who underwent prostate biopsy in our academic tertiary care center between 11/2016 and 10/2019 was prospectively collected. We developed a clinical prediction model for the detection of high-grade PCa (Gleason score ≥7) based on a multivariable logistic regression model incorporating age, PSA, prostate volume, digital rectal examination, family history, previous negative biopsy, 5-alpha-reductase inhibitor use and MRI PI-RADS score. BioPrev-C performance was externally validated in another prospective Swiss cohort and compared with two other PCa risk-calculators (SWOP-RC and PBCG-RC).

Results:

Of 391 men in the development cohort, 157 (40.2%) were diagnosed with high-grade PCa. Validation of the BioPrev C revealed good discrimination with an area under the curve for high-grade PCa of 0.88 (95% Confidence Interval 0.82-0.93), which was higher compared to the other two risk calculators (0.71 for PBCG and 0.84 for SWOP). The BioPrev-C revealed good calibration in the low-risk range (0 - 0.25) and moderate overestimation in the intermediate risk range (0.25 - 0.75). The PBCG-RC showed good calibration and the SWOP-RC constant underestimation of high-grade PCa over the whole prediction range. Decision curve analyses revealed a clinical net benefit for the BioPrev-C at a clinical meaningful threshold probability range (≥4%), whereas PBCG and SWOP calculators only showed clinical net benefit above a 30% threshold probability.

Conclusion:

BiopPrev-C is a novel contemporary risk calculator for the prediction of high-grade PCa. External validation of the BioPrev-C revealed relevant clinical benefit, which was superior compared to other well-known risk calculators. The BioPrev-C has the potential to significantly and safely reduce the number of men who should undergo a prostate biopsy.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2024 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2024 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Suiza